Novel Bispecific Immunotherapy Shows Promise Across Multiple Cancer Types in Early Clinical Trial
Key Insights
A novel bispecific immunotherapy drug, tebotelimab, demonstrated encouraging response rates across multiple advanced cancer types by simultaneously blocking PD-1 (search) and LAG-3 (search) immune checkpoints in a 269-patient international trial.
The drug achieved a 34% tumor reduction rate in eligible participants with various solid tumors and blood cancers, representing a significant advance for patients whose cancers had stopped responding to other therapies.
When combined with margetuximab for HER2 (search)-positive cancers, tebotelimab showed a 19% response rate in an additional 84 patients, far exceeding the typical near-zero response rate in this patient population.
A groundbreaking bispecific immunotherapy drug has demonstrated promising efficacy across multiple advanced cancer types while maintaining a favorable safety profile, according to results from an international early-phase clinical trial published in Nature Medicine. The study, led by physician-scientists from UPMC Hillman Cancer Center (search), represents a significant advancement in cancer immunotherapy with potential implications for treatment-resistant malignancies.
Novel Dual-Target Approach
The investigational drug tebotelimab represents a first-in-class bispecific checkpoint inhibitor that simultaneously blocks two critical immune system proteins: PD-1 (search) and LAG-3 (search). Unlike conventional checkpoint inhibitors that target a single pathway, this dual-targeting approach aims to more efficiently unleash the patient's immune system against cancer cells.
"No approved cancer drugs are like this. It is truly a novel development in the field," said lead author Dr. Jason Luke, director of the Immunotherapy and Drug Development Center at UPMC Hillman and associate professor of hematology and oncology at the University of Pittsburgh School of Medicine. "The patients in our trial had cancers that were not responding to other therapies, so to see double-digit response rates is encouraging."
Clinical Trial Results
The research team enrolled 269 patients with advanced disease across multiple cancer types, including ovarian, breast, head and neck, cervical, and lymphoma (search) cancers. All participants had treatment-resistant malignancies that had failed to respond to other therapeutic approaches.
The primary efficacy endpoint showed tumor size reduction in 34% of eligible participants, a notable achievement given the refractory nature of these cancers. The bispecific drug demonstrated activity across the diverse tumor types included in the study, suggesting broad therapeutic potential.
Enhanced Activity in HER2-Positive Cancers
In an expanded cohort, investigators enrolled an additional 84 patients with advanced HER2 (search)-positive cancers to evaluate tebotelimab in combination with margetuximab, an approved HER2-targeted therapy. This combination achieved a 19% response rate, which Luke characterized as "impressive given the response rate is usually closer to 0% in these particular patients."
Safety Profile and Mechanistic Advantages
The bispecific approach offers several theoretical advantages over combination therapy with two separate checkpoint inhibitors. When administered as a single bispecific agent, tebotelimab ensures that both PD-1 (search) and LAG-3 (search) blocking activities occur on the same immune cells, potentially generating greater immune activation compared to separate drugs that may not specifically bind together.
Importantly, the safety profile of tebotelimab was comparable to single-agent checkpoint inhibitors, avoiding the increased toxicity typically associated with combination immunotherapy regimens. This represents a significant clinical advantage, as it allows for dual pathway inhibition without compromising patient tolerability.
Future Development Strategy
Luke outlined the next steps for tebotelimab development, emphasizing the need for biomarker-driven patient selection. "The next step is to develop a biomarker test that will tell doctors which patients have cancers that are expressing the proteins that tebotelimab is designed to block and then conduct another trial to see if outcomes are improved further," he explained.
Future clinical investigations may also explore combinations with chemotherapy or radiation therapy to potentially enhance therapeutic outcomes. The broad activity observed across multiple cancer types supports continued development in various tumor settings.
"The early suggestion of response across multiple cancer types is intriguing," Luke noted. "This deserves further study, especially since this early phase trial gave us much more certainty around the safety of tebotelimab."
The research was sponsored by MacroGenics, the company developing tebotelimab, highlighting the collaborative approach between academic medical centers and pharmaceutical industry in advancing novel cancer therapeutics.